Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Safer Therapeutics Through Early Toxicity Detection

Objectif

The development of safer and more effective medicines is constrained by the late detection of drug-induced toxicity, one of the principal causes of attrition during drug development and a major contributor to escalating costs. Existing screening strategies are primarily designed to identify target engagement, whereas toxic liabilities frequently become apparent only during advanced preclinical studies or clinical trials, resulting in costly failures and significant delays in bringing new therapies to patients.

This ERC Proof-of-Concept project capitalises on discoveries arising from the ERC Consolidator Grant Form and Function of the Mitochondrial Retrograde Response (FIRM, ERC-2018-COG-819600), which identified mitochondrial pathway 18 (MP-18), a previously unrecognised and highly conserved stress-response pathway that is rapidly activated following cellular injury.

Importantly, MP-18 is triggered at an early stage of mitochondrial dysfunction, preceding conventional indicators of cellular toxicity. We will translate this discovery into a first-in-class live-cell toxicity detection platform by engineering mammalian reporter cell lines that generate a dual-colour fluorescent readout upon MP-18 activation. This ratiometric system enables real-time quantification of cellular stress while simultaneously measuring compound efficacy and toxicity within a single assay. Unlike existing approaches, the platform eliminates the need for endpoint measurements, pathogen manipulation, or separate toxicity assays, making it inherently scalable and readily compatible with high-throughput drug screening.

The project will deliver a validated MP-18 reporter assay prototype positioned for integration into pharmaceutical discovery pipelines, supported by a robust intellectual property strategy and a clear route to commercialisation. By enabling the earlier and more reliable identification of toxic compounds, this technology has the potential to reduce attrition, lower development costs, substantially reduce reliance on animal testing in line with the 3Rs principles, and accelerate the development of safer and more effective medicines.

Champ scientifique (EuroSciVoc)

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2026-POC

Voir tous les projets financés au titre de cet appel

Institution d’accueil

QUEEN MARY UNIVERSITY OF LONDON
Contribution nette de l'UE
€ 150 000,00
Coût total
Aucune donnée

Bénéficiaires (1)